Cite

MLA Citation

    John Mascarenhas et al.. “Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.” Leukemia & lymphoma, vol. 60, no. 5, 2019, pp. 1343–1345. http://access.bl.uk/ark:/81055/vdc_100081081089.0x000038
  
Back to record